In studies evaluating resistance in patients with BRAF mutations, the primary resistance rates were observed to be 36% in mutant-BRAF tumours and 33% in wild-type-BRAF tumours when PD-1 inhibitors were used as the first-line therapy. Here, PDCD1 is linked to neoplasm.